|
【结 构 式】 
|
【分子编号】49131 【品名】(1R)-9-(allyloxy)-1-heptyl-16,16-dimethyl-9,14-dioxo-6-[(3-oxotetradecanoyl)amino]-4,8,10,15-tetraoxa-13-aza-9lambda(5)-phosphaheptadec-1-yl (Z)-5-dodecenoate 【CA登记号】 |
【 分 子 式 】C49H91N2O11P 【 分 子 量 】915.242182 【元素组成】C 64.3% H 10.02% N 3.06% O 19.23% P 3.38% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(XV)After conversion of amine (XIV) to the ketoamide (XV), the N-Boc group was cleaved with trifluoroacetic acid to provide the primary amine (XVI). Condensation of adipic acid (XVII) with amine (XVI) in the presence of EDC gave rise to the diamide (XVIII).
| 【1】 Rossignol, D.P.; Ishizaka, S.T.; Nault, A.; Lewis, M.; Rose, J.; McGuiness, P.; Hawkins, L.D. (Eisai Co., Ltd.); Immunological adjuvant cpd.. EP 1147117; US 6290973; WO 0044758 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XIV) | 49130 | (1R)-9-(allyloxy)-6-amino-1-heptyl-16,16-dimethyl-9,14-dioxo-4,8,10,15-tetraoxa-13-aza-9lambda(5)-phosphaheptadec-1-yl (Z)-5-dodecenoate | C35H67N2O9P | 详情 | 详情 | |
| (XV) | 49131 | (1R)-9-(allyloxy)-1-heptyl-16,16-dimethyl-9,14-dioxo-6-[(3-oxotetradecanoyl)amino]-4,8,10,15-tetraoxa-13-aza-9lambda(5)-phosphaheptadec-1-yl (Z)-5-dodecenoate | C49H91N2O11P | 详情 | 详情 | |
| (XVI) | 49132 | (1R)-9-(2-aminoethoxy)-1-heptyl-9-oxo-6-[(3-oxotetradecanoyl)amino]-4,8,10-trioxa-9lambda(5)-phospha-12-tridecen-1-yl (Z)-5-dodecenoate | C44H83N2O9P | 详情 | 详情 | |
| (XVII) | 49133 | Hexanedioic acid; Hexanedioic acid; 1,6-Hexanedioic acid; 1,4-Butanedicarboxylic acid; Adipic acid | 124-04-9 | C6H10O4 | 详情 | 详情 |
| (XVIII) | 49134 | (1R,32R,38Z)-9,24-bis(allyloxy)-1,32-diheptyl-9,14,19,24,34-pentaoxo-6,27-bis[(3-oxotetradecanoyl)amino]-4,8,10,23,25,29,33-heptaoxa-13,20-diaza-9lambda(5),24lambda(5)-diphospha-38-pentatetraconten-1-yl (Z)-5-dodecenoate | C94H172N4O20P2 | 详情 | 详情 |
Extended Information